理气活血滴丸治疗冠心病心绞痛临床疗效的Meta分析

Meta-analysis of the clinical efficacy of Liqi Huoxue drop pill in the treatment of angina pectoris in coronary artery disease

目的:采用Meta分析系统评价理气活血滴丸治疗冠心病心绞痛的疗效。方法:使用计算机检索数据库,从建立起截止到2022年2月1日,包括英文数据库PubMed、Embase、Web of Science、Cochrane Library和中文数据库中国知网、维普、万方数据、中国生物医学数据库,搜索有关理气活血滴丸联合西药治疗冠心病心绞痛的随机对照试验(RCT)。由两名研究者独立进行数据提取,并对所纳入研究的文献质量进行评估。采用Revman5.4软件对所纳入的文献进行荟萃分析。结果:纳入9项研究,共计982例患者。Meta分析结果显示,应用西药常规治疗联合理气活血滴丸的观察组优于西药常规治疗的对照组。干预组的临床疗效[RR=1.20,95%CI=(1.12,1.29),P<0.00001]、心绞痛症状疗效[RR=1.17,95%CI=(1.07,1.29),P=0.001]、心绞痛发作次数[SMD=-2.26,95%CI(-4.10,-0.42),P=0.002]、白细胞介素-6[MD=-4.65,95%CI(-6.91,-2.39),P<0.0001]、白细胞介素-18[MD=-2.53,95%CI(-2.84,-2.22),P<0.00001]、高敏C反应蛋白[MD=-0.08,95%CI(-1.81,-0.75),P<0.00001]、内皮功能指标一氧化氮[MD=8.03,95%CI(0.93,15.14),P=0.03]均优于对照组(西医常规治疗),差异均有统计学意义(P<0.05)结论:冠心病心绞痛患者在常规西药治疗的基础上联合理气活血滴丸,可以有效改善患者临床疗效、心绞痛症状疗效、心绞痛发作次数、血清炎性指标白细胞介素-6、白细胞介素-18、高敏C反应蛋白、内皮功能NO指标,为理气活血滴丸联合西药治疗冠心病心绞痛提供了可靠的循证依据。

Objective:To evaluate the efficacy of Liqi Huoxue dropping pills in the treatment of angina pectoris in coronary heart disease using the Meta-analysis system.Methods:Randomized controlled trials(RCT)on the treatment of angina pectoris in coronary artery disease with the combination of Western medicine with Liqi Huoxue drop pills were searched using computerized search databases,including English databases PubMed,Embase,Web of Science,The Cochrane Library and Chinese databases CNKI,VIP,WanFang Data and CBM from the time of establishment until February 1,2022.Data extraction was performed independently by two investigators and the quality of the literature of the included studies was assessed.A meta-analysis of the included literature was performed using Revman 5.4 software.Results:Nine studies with a total of 982 patients were included.The results of Meta-analysis showed that the observation group,which adopted conventional treatment of Western medicine combined with Li qi huo xue dropping pills,was better than the control group,which was treated with conventional Western medicine alone.Clinical efficacy of the intervention group[RR=1.20,95%CI=(1.12,1.29),P<0.00001],Angina pectoris symptom treatment[RR=1.17,95%CI=(1.07,1.29),P=0.0010],Number of angina attacks[SMD=-2.26,95%CI(-4.10,-0.42),P=0.002],IL-6[MD=-4.65,95%CI(-6.91,-2.39),P<0.0001],IL-18[MD=-2.53,95%CI(-2.84,-2.22),P<0.00001],HS-CRP[MD=-0.08,95%CI(-1.81,-0.75),P<0.00001],and NO[MD=8.03,95%CI(0.93,15.14),P=0.03]were significantly different and better than the control group(western conventional treatment),and the differences were all statistically significant.Conclusion:Combining Liqi Huoxue drop pill with conventional Western medicine for patients with coronary angina can effectively improve the clinical efficacy,the efficacy of angina symptoms,the number of angina attacks,serum inflammatory indexes interleukin-6,interleukin-18,high-sensitivity C-reactive protein,and endothelial function NO indexes in patients with coronary angina,providing a reliable evidence-based basis for combining Liqi Huoxue drop pill with Western medicine for the treatment of coronary angina.